Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2012 - 2026)

Enanta Pharmaceuticals' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $34.9 million for Q1 2026.

• Quarterly Cash & Equivalents fell 41.99% year-over-year to $34.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.9 million (down 41.99% YoY) and the FY2025 annual result came in at $32.3 million, down 13.25% from the prior year.
• Cash & Equivalents was $34.9 million for Q1 2026 at Enanta Pharmaceuticals, down from $37.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $95.2 million in Q2 2023 and bottomed at $28.4 million in Q2 2022.
• A 5-year average of $51.8 million and a median of $42.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 516.54% — and 2024, when it tumbled 62.41%.
• Enanta Pharmaceuticals' Cash & Equivalents stood at $42.2 million in 2022, then slipped by 5.42% to $39.9 million in 2023, then surged by 111.23% to $84.3 million in 2024, then tumbled by 55.62% to $37.4 million in 2025, then slipped by 6.7% to $34.9 million in 2026.
• Business Quant data shows ENTA's Cash & Equivalents at $34.9 million in Q1 2026, $37.4 million in Q4 2025, and $32.3 million in Q3 2025.